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Abstract
Objective A randomised experimental study was used to
evaluate the therapeutic effect of a selective cyclooxy-
genase-2 (COX-2) inhibitor in neurogenic laryngitis.
Materials and methods Male Wistar Han rats were sub-
jected to the nasogastric intubation model (NGI) of
laryngitis for 1 and 2 weeks. The NGI animals were divi-
ded into three groups: (1) treated with COX-2 inhibitor
Etoricoxib, (2) vehicle and (3) non-intubated animals. A
fourth group of animals was submitted to NGI only. Lar-
yngeal sections were immunostained for substance P (SP)
and calcitonin gene-related peptide (CGRP) fibre-immuno-
reactivity (IR) and quantification of COX-2 positive
cells through stereological analysis. The expression of
COX-2, interleukins IL-1b, IL-6, IL-10 and tumour
necrosis factor-a (TNF-a) was determined by quantitative
real time QRT-PCR.
Treatment Etoricoxib (6 mg/kg/day) was prepared in
0.9% sterile saline with 5% glucose (vehicle) and admin-
istered daily during 1 or 2 weeks.
Results Treatment for 1 week with Etoricoxib attenuated
the CGRP-IR fibre depletion, the COX-2-IR increased cell
number and the TNF-a and COX-2 mRNA increased levels
induced by NGI. Two weeks of treatment had no beneficial
effect.
Conclusions Etoricoxib is effective in neurogenic laryn-
gitis for limited periods of administration, indicating that
selective COX-2 inhibitors should be evaluated in the
future.
Keywords Neurogenic laryngitis  Nasogastric intubation
(NGI) model  Quantitative real-time QRT-PCR 
Selective COX-2 inhibitor  Tumor necrosis
factor-a (TNF-a)
Introduction
The aetiology of certain forms of laryngitis is unknown and
therapeutics may fail due to the adverse side effects of
steroidal and non-steroidal anti-inflammatory drugs
(NSAIDs) that are usually used [1–3]. Neurogenic
inflammation results from interaction between the immune
and nervous systems [4]. Neuropeptides like substance P
(SP) or calcitonin gene related peptide (CGRP) [4, 5],
which are contained in peripheral sensitive nerve fibres, are
released by terminals of primary afferents in inflammatory
actions induced by several stimuli [5, 6]. Some studies
showed a neurogenic component in some pathologies like
asthma, rhinitis and rheumatoid arthritis [8]. Recently, we
demonstrated a neurogenic factor in a new model of
experimental laryngitis [9]. The intraepithelial nerve fibres
of the larynx are important for bronchopulmonar defence
[10]. These fibres project into the laryngeal lumen and are
rich in SP and CGRP [10]. The release of these neuro-
peptides can induce neurogenic laryngitis as shown by the
increased expression of inflammatory cytokines like inter-
leukin-1b (IL-1b), IL-6 and tumour necrosis factor-a
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(TNF-a), and the decreased expression of the anti-inflam-
matory cytokine IL-10 [9].
Nasogastric intubation (NGI) is largely used in clinical
practice and can induce important respiratory disorders like
aspiration pneumonia or laryngitis [9, 11, 12]. We previ-
ously demonstrated that NGI is a good model to study
laryngitis in the rat since no direct lesion of the laryngeal
epithelium is induced [9]. Additionally, we observed an
overexpression of COX-2 enzyme in the laryngeal mucosa
[9], which represents the inducible form of the COX
enzyme following pathological stimulation in opposition to
the constitutive COX-1 isoform [3]. This indicates that
selective COX-2 inhibitors may be useful in the treatment
of this pathology, similarly to several other pathologies
where blocking of COX-2 activity by administration of
NSAIDs was shown to have an anti-inflammatory action
[13–15]. Classical non-selective NSAIDs and corticoste-
roids used to treat laryngitis have well known aerodigestive
adverse side effects when compared to the selective COX-2
inhibitors [3, 16]. Recent studies have demonstrated the
utility and sensitivity of the latter drugs in throat pain [17].
However, to the best of our knowledge, there are no
experimental studies evaluating the use of selective COX-2
selective NSAIDs in laryngitis. In order to analyse the
potential role of selective COX-2 inhibitors in neurogenic
laryngitis, we studied the effect of Etoricoxib upon the
inflammatory process in the NGI model of neurogenic
laryngitis [9], through immunohistochemical and molecu-
lar biology techniques using markers of inflammation, in
animals submitted to NGI for 1 and 2 weeks.
Materials and methods
Animals
This study was performed in 66 male rats weighing 350–
450 g, obtained from the Wistar Han colony of the
Charles River Company (Barcelona, Spain). The experi-
ments were carried out in accordance with the
Portuguese regulation for the handling of laboratory
animals (Veterinary General Directive Board, Ministry of
Agriculture, Rural Development and Fishing) and Euro-
pean Union Council Directive 86/609/EEC. Animals
were lightly anesthetized with inhaled isoflurane in order
to allow the swallowing reflex and submitted to the NGI
procedure [9]. A 10–12 cm small bore nasogastric aspi-
ration tube used for NGI in premature newborns (cat. No
533.04; Vigon Laboratoires Pharmaceutiques, Ecouen,
France) was inserted into the rat oesophagus to the
stomach lumen, with the external tip sutured to the nasal
lateral cartilages. Animals were given time to recover
and then were returned to their cages.
Animals were distributed into five groups, each one
formed by 12 animals (n = 6 for immunohistochemical
processing; n = 6 for molecular biology analysis; (6 ? 6)
95 groups, total n = 60 rats):
• NGI ? ETORI1w: submitted to NGI and treated with
Etoricoxib from the first day of intubation for 1 week;
• NGI ? ETORI2w: submitted to NGI and treated with
Etoricoxib from the first day of intubation for 2 weeks;
• NGI ? VEHIC1w: submitted to NGI and administered
0.9% sterile saline with 5% glucose for 1 week;
• NGI ? VEHIC2w: submitted to NGI and administered
0.9% sterile saline with 5% glucose for 2 weeks;
• CONT: non-intubated rats, whose larynxes were used
as naı¨ve controls.
An additional group of six animals were included for
additional histopathological comparison of COX-2-IR cells
in the laryngeal mucosa:
• NGI1w: submitted to NGI (without treatment; n = 3)
for 1 week;
• NGI2w: submitted to NGI (without treatment; n = 3)
for 2 weeks;
After completion of the intubation period, animals for
immunohistochemical experiments were perfused under
anaesthesia (isoflurane and 35% chloral hydrate, intraper-
itoneally) through the ascending aorta with 4%
paraformaldehyde in PBS 0.01 M. After confirmation that
the NGI tube was still inserted to the stomach lumen, the
larynx was removed and immersed in the same fixative
followed by 30% sucrose in 0.1 M PBS overnight. Animals
used for real time QRT-PCR studies were anesthetized
with isoflurane and sacrificed with 35% chloral hydrate
intraperitoneally. Larynxes were excised immediately,
macerated and immersed in 0.8 ml of TRIzol (Invitro-
gen, Carlsbad, CA, USA) and stored at -80C.
Drug therapy
Etoricoxib (Exxiv 60 mg, Bial, Bial-Portela & Ca., S.A.,
Trofa, Portugal) was suspended in 0.9% sterile saline with
5% glucose and administered to each animal in the dose of
6 mg/kg/day, by oral gavage, once daily.
Histology and immunohistochemistry
Laryngeal coronal frozen sections (20 lm) were obtained
with a cryostat and processed for immunohistochemistry.
Alternate sections were incubated overnight at room tem-
perature with rabbit anti-CGRP (1:6,000; Bachem, San
Carlos, CA, USA) or rabbit anti-SP (1:6,000; Bachem, San
Carlos, CA, USA) antibodies in a PBS solution 0.1 M at
pH 7.2, containing 0.3% triton X-100 (PBST). After
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washing with PBST, the sections were then incubated with
biotinylated goat anti-rabbit antibody (1:200; Vector Lab-
oratories, Burlingame, CA, USA) in PBST for 1 h, washed
in PBST and then incubated with avidin–biotin complex
(ABC) (1:200; Vector Laboratories, Burlingame, CA,
USA) in PBS for 1 h. After rinsing in PBS and 0.1 M Tris–
HCl buffer (pH 7.4) the antigen–antibody reaction was
visualised with a diaminobenzidine (DAB; Sigma–
Aldrich, St. Louis, MO, USA) solution.
COX-2 immunohistochemistry was carried out accord-
ing to the streptavidin–biotin-peroxidase complex
technique (Ultravision Detection System Anti-polyvalent,
HRP, Lab Vision Corporation, Fremont, CA, USA), using a
primary antibody raised against COX-2 protein (rabbit
monoclonal antibody, clone SP21; Neomarkers, Fremont,
CA, USA) diluted 1:400. Slides were sequentially washed
in PBS 0.02% Tween 20 and incubated with 3% H2O2 in
methanol for 10 min. This was followed by incubation with
blocking solution for 10 min and then the primary antibody
solution for 2 h, at room temperature. Sections were then
sequentially washed in PBS/0.02% Tween 20 and then
incubated with biotinylated goat anti-polyvalent antibody
for 10 min and streptavidin peroxidase for 10 min.
Immunoreaction was revealed using DAB as chromogen,
as above. Slides were counterstained with Mayer haema-
toxylin (Merck, Darmstadt, Germany). Negative controls
were performed by omission of the primary antibody. In
this case, no labelled fibers/cells of any type of IR (CGRP,
SP and COX-2) were observed in the laryngeal mucosa.
Stereological procedures
Sections were analyzed in an Axioskop 2 plus light
microscope and images of laryngeal histological data were
taken using an Axiocam HRC camera and AxioVision 3.1
software (Carl Zeiss, Go¨ttingen, Germany). Cell and fibre
numbers were estimated using the optical fractionator
method [18]. Briefly, this consists of virtual 3D-boxes
(150 lm 9 150 lm 9 30 lm) with equally spaced grids
that were superimposed by the software on every eighth
coronal laryngeal section after drawing the limits of the
area under study in the laryngeal mucosa. The number of
COX-2-IR cells and SP and CGRP immunoreactive fibres
that crossed the gridlines in every randomized site was
counted, by an experimenter blinded to both the neuro-
peptide immunoreactivity present and/or the conditions
applied (control, vehicle or treatment). The estimated
numbers were calculated from the ratio between the total
number of counted cells and fibres crossing the grid site
and the number of grid sites per area. The coefficients of
error were automatically computed by the software
according to the formulas of Gundersen for cell numbers
[18, 19].
mRNA extraction and QRT-PCR
Total mRNA in the larynx was extracted by adding CHCl3
(Sigma–Aldrich, St. Louis, MO, USA) followed by cen-
trifugation at 13,000 rpm for 15 min at 4C. The
supernatant was carefully collected and total mRNA was
precipitated using isopropanol (2-propanol, Sigma–
Aldrich, St. Louis, MO, USA) followed by centrifugation
at 13,000 rpm for 15 min at 4C. Ethanol 70% was used to
wash the mRNA pellet, which was then re-centrifuged at
9,000 rpm for 5 min at 4C. The supernatant was carefully
discarded and the pellet was air dried at 4C. Finally, the
pellet was resuspended with 50 ll of DNAse/RNAse free
distilled water (Invitrogen, Carlsbad, CA, USA). Total
mRNA was quantified by spectrophotometry using the
NanoDrop equipment (NanoDrop Technologies, Wil-
mington, DE, USA). Subsequently, samples of total mRNA
with the same concentration (2 ng/10 ll) were reverse
transcribed in a thermocyclator My Cycler Thermal
Cycler (Bio-Rad, Hercules, CA, USA) using a Superscript
Kit II (Invitrogen, Carlsbad, CA, USA), and Oligo dT
(Invitrogen, Carlsbad, CA, USA). Reverse transcription
was performed at 42C for 60 min followed by RT inac-
tivation at 70C for 15 min. The cDNA was then subjected
to reverse transcription polymerase chain reaction (real
time QRT-PCR) procedures for quantification of laryngeal
mRNA levels of b-Actin, IL-1b, TNF-a, IL-6, IL-10 and
COX-2, using the LightCycler (Roche, Indianapolis, IN,
USA) and a SYBR Green PCR Master Mix (QIAGEN
GmbH, Hilden, Germany) according to the manufacturer’s
instructions. Primer sequences used to amplify various
cDNAs are shown in Table 1 and have been used previ-
ously by our group [9]. A typical QRT-PCR protocol was
performed under the following conditions: a 15 min hot
start at 95C, followed by 40 three-temperature cycles
(94C denaturing for 15 s; 58C annealing for 20 s; and
72C extension for 15 s), melting at 60C until 95C for
90 s and finally cooling to 35C. Melting point analysis
was used to confirm the specificity of the SYBR Green
assays. Gene expression of the housekeeping gene b-actin
was used for normalization. Target mRNA relative
expression was calculated using dCT (change in cycling
threshold) [20].
Data analysis
Results are expressed after statistic analysis using SPSS
version 17.0 for Windows (SPSS Inc, Chicago, IL, USA).
For each neuropeptide, enzyme or cytokine analysed, a
double statistical evaluation was performed: (a) data means
for each of the five groups (CONT, NGI ? VEHIC1w, NGI
? ETORI1w, NGI ? VEHIC2w and NGI ? ETORI2w)
were compared using one-way ANOVA statistical
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evaluation followed by Tukey HSD post hoc test; (b) a
two-way ANOVA was performed to compare the effect of
time with the effect of treatment in order to evaluate pos-
sible interactions between time and treatment; this second
evaluation did not include the control group (CONT). The
normal distribution of data was verified using the
Kolmogorov–Smirnov test, whereas the equality of vari-
ances was verified by the Levene test. When the latter was
not observed the Kruskal–Wallis non-parametric test was
used. Differences were considered to be significant when
p \ 0.05. Statistical significances are not presented in
Figs. 1, 4, 5 and 6 to preserve the clarity of the figure, but
are detailed in ‘‘Results’’.
Results
Etoricoxib blocks the decrease of CGRP-IR fibers
induced by 1-week NGI
The experimental NGI model of laryngitis and therapeuti-
cal protocol using Etoricoxib induced different changes in
the expression of neurogenic peptides at the end of both the
first and second weeks (ANOVA, CGRP p \ 0.0001; SP
p \ 0.0001) (Figs. 1, 2, 3).
After the first week, there was a significant decrease in the
number of CGRP-IR (Figs. 1a, 2a, b) and SP-IR (Figs. 1b,
2d, e) fibres in the NGI group, when compared with non-
intubated animals (NGI ? VEHIC1w 9 CONT, CGRP
p \ 0.0001; SP p \ 0.001, Tukey test). The 1-week therapy
with Etoricoxib reverted the decrease in the number of
CGRP-IR fibres to control levels (NGI ? ETORI1w 9
NGI ? VEHIC1w, p \ 0.002; NGI ? ETORI1w 9
CONT, p [ 0.05, Tukey test) (Figs. 1a, 2c). However, it
did not affect the decrease in the levels of SP-IR fibres
observed in the NGI plus vehicle group (NGI ?
Table 1 Sequences of primers used for real-time PCR
Target Oligo Sequence Gene Bank ACC
b-Actin Forward primer 50-GATTTGGCACCACACTTTCTACA-30 NM_031144
Reverse primer 50-ATCTGGGTCATCTTTTCACGGTTGG-30
IL-1b Forward primer 50-GAAACAGCAATGGTCGGGAC-30 M98820
Reverse primer 50-GAGACCTGACTTGGCAGAGG-30
TNF-a Forward primer 50-CCAACAAGGAGGAGAAGTTC-30 NM_012675
Reverse primer 50-CCTGGTGGTTTGCTACGAC-30
IL-6 Forward primer 50-CAAGAGACTTCCAGCCAG-30 NM_012589
Reverse primer 50-CTCCGACTTGTGAAGTGGT-30
IL-10 Forward primer 50-GCCAAGCCTTGTCAGAAATGA-30 NM_012854
Reverse primer 50-TTTCTGGGCCATGGTTCTCT-30
COX-2 Forward primer 50-TTTGTTGAGTCATTCACCAGACAGAT-30 S67722
Reverse primer 50-ACGATGTGTAAGGTTTCAGGGAGAAG-30
CGRPA
SPB
NGI+Etori NGI+Etori
NGI+Etori NGI+Etori
Fig. 1 Effect of Etoricoxib treatment upon CGRP-IR (a) and SP-IR (b)
fibre immunoreactivity after 1 and 2 weeks of NGI. Note that the
decrease in CGRP-IR fibres was rescued with Etoricoxib treatment after
the first, but not the second week of NGI. The decrease induced in SP-IR
fibres was not rescued by the treatment. Values shown as mean ± SD.
Asterisks and dots represent outliers. Statistical significances are not
presented for clarity of the figure, but are specified in ‘‘Results’’
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ETORI1w 9 NGI ? VEHIC1w, p [ 0.05; NGI ? ETORI1w
9 CONT, p \ 0.002, Tukey test) (Figs. 1b, 2f).
At the end of the second week, there was a decrease in the
number of CGRP-IR fibres in NGI plus vehicle (NGI ?
VEHIC2w 9 CONT, p \ 0.0001, Tukey test) (Figs. 1a, 3a,
b) and NGI animals treated with Etoricoxib (NGI ?
ETORI2w 9 CONT, p \ 0.001, Tukey test) (Figs. 1a, 3a, c).
Regarding SP-IR fibres, the same results were observed in
both groups (NGI ? VEHIC2w 9 CONT, p \ 0.005,
Tukey test) (Figs. 1b, 3d, e) (NGI ? ETORI2w 9 CONT,
p \ 0.001, Tukey test) (Figs. 1b, 3d, f).
Finally, there was a significant interaction between time
and treatment upon the level of CGRP-IR fibers
(time 9 treatment effect, p \ 0.018, two-way ANOVA).
However, time, treatment or time 9 treatment had no
effect on SP-IR fibers.
Etoricoxib blocks the increase of TNF-a mRNA
expression induced by 1-week NGI
The NGI experimental model induced significant changes in
inflammatory mediators at the laryngeal mucosa. TNF-a
(one-way ANOVA, p \ 0.0001) mRNA levels increased
significantly after 1 and 2 weeks of NGI (NGI ? VE-
HIC1w 9 CONT, p \ 0.0001; NGI ? VEHIC2w 9 CONT,
p \ 0.0001, Tukey test) (Fig. 4). After a 1-week treatment
with Etoricoxib (NGI ? ETORI1w), the specific COX-2
inhibitor blocked the increase of TNF-a expression induced
by NGI, reducing it to values similar to those observed in
control animals (NGI ? ETORI1w 9 NGI ? VEHIC1w,
p \ 0.0001; NGI ? ETORI1w 9 CONT, p [ 0.05, Tukey
test). However, no significant reduction of TNF-a mRNA
expression was observed after 2 weeks of treatment with
Fig. 2 Photomicrographs of
CGRP-IR (a–c) and SP-IR (d–f)
sensitive fibres in the laryngeal
mucosa in naı¨ve (control)
animals (a, d) and following
1 week of NGI in both vehicle-
treated (b, e) and Etoricoxib-
treated animals (c, f). After
1 week, there is a clear
reduction in the presence of
CGRP and SP immunoreactive
fibres in the mucosa induced by
NGI (b, e) and the recovery of
CGRP-IR to control levels
allowed by the treatment with
Etoricoxib (c). IR was revealed
using DAB as chromogen.
Arrows fibres
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Etoricoxib (Fig. 4). Finally, there was a loose interaction
between time and treatment reaching the border of signifi-
cance (time 9 treatment effect, p \ 0.08, two-way
ANOVA).
Concerning IL-1b expression (one-way ANOVA,
p \ 0.0001), treatment with Etoricoxib did not affect the
level of expression after the first week, but increased mRNA
values (NGI ? ETORI2w 9 CONT, p \ 0.008, Tukey test)
after 2 weeks (Fig. 5a). No interaction was observed
between time and treatment, but there was a significant effect
with treatment (treatment effect, p = 0.03, two-way
ANOVA). IL-6 levels in the larynx of both groups of intu-
bated rats was increased (Vehicle and Etoricoxib, after 1 or
2 weeks) (Kruskal–Wallis, p \ 0.002), but there was no
effect of Etoricoxib treatment upon laryngeal levels of this
cytokine, with a trending increase in IL-6 levels after a
2-week treatment (although not statistically significant). A
borderline interaction between time and treatment was close
to statistical significance (analysis of four groups excluding
controls, p [ 0.051, two-way ANOVA (Fig. 5b). In the case
of IL-10 (one-way ANOVA, p \ 0.017), NGI induced an
increase in the expression after 2 weeks (NGI ?
VEHIC2w 9 CONT, p \ 0.012, Tukey test), which was
ameliorated after treatment with Etoricoxib (NGI ?
ETORI2w 9 NGI ? VEHIC2w, p \ 0.041, Tukey test)
(Fig. 5c). Even though no interaction between time and
treatment was present, there was a significant effect with
treatment (treatment effect, p \ 0.046, two-way ANOVA).
Etoricoxib blocks the increase of COX-2 IR and mRNA
levels induced by 1-week NGI
Changes in the expression of COX-2 were detected by
increases in both mRNA levels recorded by QRT-PCR
Fig. 3 Photomicrographs of
CGRP-IR (a–c) and SP-IR (d–f)
sensitive fibres in the laryngeal
mucosa in naı¨ve (control)
animals (a, d) and in animals
submitted to NGI for 2 weeks,
treated either with vehicle (b, e)
or with the selective COX-2
inhibitor Etoricoxib (c, f). Two
weeks of treatment with
Etoricoxib did not rescue (c, f)
the reduction of laryngeal
neuropeptidergic fibres (CGRP-
IR and SP-IR) induced by NGI
(b, e). IR was revealed using
DAB as chromogen. Arrows
fibres
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(one-way ANOVA, p \ 0.0001) (Fig. 6a) and in the
number of COX-2-IR cells by stereological procedures
(one-way ANOVA, p \ 0.01) (Figs. 6b, 7, 8). In what
concerns laryngeal mRNA levels of COX-2, no expression
was detected in the CONT group (Fig. 6a). After 1 week of
NGI the values increased significantly (NGI ? VE-
HIC1w 9 CONT, p \ 0.01, Tukey test), with the
Etoricoxib treatment being effective in reducing mRNA
levels (NGI ? ETORI1w 9 NGI ? VEHIC1w, p \ 0.047,
Tukey test) to the negligible levels of controls (Fig. 6a).
After 2 weeks of treatment, there was a tendency for
reduction of the increased COX-2 mRNA levels observed
in the NGI ? VEHIC group, although it did not reach
statistical significance (Fig. 6a). Even though no interac-
tion between time and treatment was present, there was a
significant effect with both time (time effect, p \ 0.001,
two-way ANOVA) and treatment (treatment effect,
p \ 0.001, two-way ANOVA).
Concerning the presence of laryngeal cells expressing
COX-2, there was an increased number after the first week of
NGI when compared to non-intubated animals (NGI ?
VEHIC1w 9 CONT, p \ 0.009, Tukey test) (Figs. 6b, 7a–d),
which was also reverted at the end of first week of treatment
with Etoricoxib (Figs. 6b, 7a–c, e, f), but not after the second
week (NGI ? ETORI1w 9 NGI ? VEHIC1w, p = 0.01;
NGI ? ETORI2w 9 NGI ? VEHIC2w, p [ 0.05, Tukey
test) (Figs. 6b, 8). Additionally, there was a significant
interaction between time and treatment (time 9 treatment
effect, p \ 0.002, two-way ANOVA).
TNF-α
Fig. 4 Effect of Etoricoxib treatment upon the relative mRNA
expression of TNF-a after 1 and 2 weeks of NGI. The selective COX-2
inhibition decreased the TNF-a expression induced by NGI after
1 week of treatment, mimicking the control levels, but not after
2 weeks. All values are normalized to b-actin (reference gene).
Values shown as mean ± SD. Asterisks and dots represent outliers.
Statistical significances are not presented for clarity of the figure, but
are specified in ‘‘Results’’. Relative expression of target mRNA was
calculated using dCT (change in cycling threshold) [20]
IL-1βA
IL-6B
IL-10C
NGI+Etori NGI+Etori
NGI+Etori NGI+Etori
Fig. 5 Effect of Etoricoxib treatment upon the relative mRNA
expression of IL-1b (a), IL-6 (b) and IL-10 (c) in the laryngeal
mucosa, after 1 and 2 weeks of NGI. Animals treated with Etoricoxib
showed a tendency for higher levels of IL-1b and IL-6 and lower
levels of IL-10 than NGI plus vehicle after 2 weeks of nasogastric
intubation. All values are normalized to b-actin (reference gene).
Values shown as mean ± SD. Asterisks and dots represent outliers.
Statistical significances are not presented for clarity of the figure, but
are specified in ‘‘Results’’. Relative expression of target mRNA was
calculated using dCT (change in cycling threshold) [20]
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Discussion
Classical NSAIDs are the most commonly used drugs for
the treatment of pain and inflammation in a wide range of
diseases, including ear, nose and throat conditions [21–23].
These drugs act primarily by blocking the synthesis of
prostaglandins by cyclooxygenase (COX) enzymes [13,
21]. Their therapeutic effects are related to the inhibition of
inflammation-induced COX-2, whereas their most common
side effects are related to the inhibition of the constitutive
COX-1 enzyme [21, 24, 25]. Interestingly, aerodigestive
and cutaneous adverse events related to the use of NSAIDs
are known to be one of the most common in medicine [21].
Contrarily to the classical NSAIDs that inhibit both
isoforms of COX enzymes, the selective COX-2 inhibitors
like Etoricoxib, mainly block the activity of the inducible
COX-2 enzyme [13, 14, 21, 24, 25]. This may result in a
better tolerability profile, with less associated side effects.
However, to the best of our knowledge, there are no indi-
cations in clinical practice to the use of the latter drugs in
laryngitis, probably because the expression of the COX-2
enzyme in the larynx and the potential therapeutic effects
of these drugs have not been explored in detail. In clinics
and in experimental studies, NGI induced laryngitis and
COX-2 overexpression in inflammatory laryngeal cells
have already been shown [9, 11]. In the present study, by
showing decreased levels of COX-2 and TNF-a and
reversion of depletion of the neurogenic CGRP peptide at
the end of the first week of treatment, NGI animals treated
with a selective COX-2 inhibitor Etoricoxib revealed an
anti-inflammatory effect of this drug during the first week
of laryngitis.
Animals submitted to 1 week of nasogastric intubation
(NGI ? VEHIC1w group) showed increased COX-2, TNF-a
and IL-6 mRNA levels, as well as an increased number of
laryngeal cells immunoreactive to COX-2. These data are
in accordance with studies including other inflammatory
conditions, where these molecules were also significantly
increased [26, 27]. TNF-a and IL-6 induce COX-2
expression [28] and are known to induce the release of the
pro-inflammatory neuropeptides SP and CGRP in different
tissues [26, 29]. On the other hand, SP and CGRP are also
potent inducers of the production of pro-inflammatory
cytokines, such as IL-1b, IL-6 and TNF-a [4, 5]. In the
group submitted to NGI and treated simultaneously with
Etoricoxib (NGI ? ETORI1w), COX-2 and TNF-a mRNA
levels decreased, as well as the number of laryngeal cells
immunoreactive to COX-2. This is indicative of an anti-
inflammatory action of Etoricoxib in the larynx of intu-
bated rats. However, no changes were observed in the IL-6,
IL-1b and IL-10 mRNA levels. This could be conflicting
data because Etoricoxib inhibits the nuclear factor kappa B
(NF-jB) [24, 25, 27, 30, 31], an important mediator in
many inflammatory conditions, and thus the levels of these
interleukins were expected to be altered. These results may
be explained by the occurrence of alternative pathways of
cytokine production, possibly by alterations of the activity
of cellular kinases, such as Erk, p38 MAPK or Cdks [32,
33]. Another possible explanation is the presence of a
counterbalanced production of interleukins, as other
selective COX-2 inhibitors have shown the capacity to
induce IL-6 production instead of reducing it [24, 25, 34].
Concerning the period of 2 weeks of NGI, compared to
controls, there was an increase in the levels of IL-6, TNF-a,
IL-10 and COX-2 mRNA expression in the NGI ? VE-
HIC2w group, confirming the presence of a marked
COX-2 - mRNAA
COX-2 – Nr of cellsB
NGI+Etori NGI+Etori
NGI+EtoriNGI+Etori
Fig. 6 Effect of Etoricoxib treatment upon laryngeal inflammation
measured by COX-2 levels of mRNA (a) and COX-2-immunoreac-
tive cells (b) present in the mucosa after 1 and 2 weeks of NGI. Note
that the drug was effective only at the first week by reducing both the
levels of mRNA and the number of COX-2-IR cells to control levels.
Values shown as mean ± SD. Asterisks and dots represent outliers.
Statistical significances are not presented for clarity of the figure, but
are specified in ‘‘Results’’. Relative expression of target mRNA was
calculated using dCT (change in cycling threshold) [20]
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inflammatory process in these animals. The treatment with
Etoricoxib after 2 weeks of intubation (NGI ? ETORI2w)
induced an increase in IL-1b and IL-6 mRNA levels and a
decrease in IL-10 expression, which did not occur in the
NGI ? VEHIC2w group. The increased levels of IL-10
mRNA in the NGI ? VEHIC group can be seen as an
immunologic anti-inflammatory response [35, 36] that is
aborted by Etoricoxib, whereas the increase in IL-6 can be
explained by the capacity of selective COX-2 inhibitors to
induce IL-6 production [24, 25, 36]. It is also possible that
COX-2 inhibitors can induce IL-1b and IL-6 production
and a decrease in the levels of IL-10 by the loss in the
activity of protective cellular molecules like hepatocyte
growth factor (HGF). Since HGF decreases IL-1b and IL-6
and increases IL-10 through the upregulation of COX-2
[37], a prolonged COX-2 inhibition might lead to a
blockade of HGF function, which would induce IL-1b and
IL-6 overexpression and a decrease of IL-10 levels. Further
studies are needed to elucidate this possibility. Concerning
the TNF-a and COX-2 expression, which were decreased
by Etoricoxib after 1 week of NGI, the values obtained
following 2 weeks of treatment were similar to the
NGI ? VEHIC2w group, which seems to indicate a loss of
therapeutic effect of the drug after long periods of
administration [15, 33].
Regarding neuropeptides, in this model of laryngitis,
Etoricoxib attenuated the depletion of CGRP from lar-
yngeal primary afferents after 1 week of NGI, but SP-IR
was not altered. In our previous studies, we observed less
SP-IR fibres than CGRP-IR fibres in the larynx [10]. This
finding suggests that CGRP is the most important neuro-
peptide present in the laryngeal epithelium [9, 10].
Accordingly, the most significant neurogenic anti-inflam-
matory action of COX-2 inhibitors shown in the present
work seems to occur through a CGRP-mediated mecha-
nism. CGRP receptors are co-localized with prostaglandin
Fig. 7 Histological changes in
the connective tissue of the
laryngeal mucosa induced by
nasogastric intubation (NGI).
The presence of an
inflammatory infiltrate after
NGI as compared to CONT is
evident (circles a, d).
Inflammatory signs are also
present in intubated animals
submitted to vehicle for 1 week
(NGI ? VEHIC1w), namely
inflammatory cells (circle b),
edema and hypertrophy of the
mucosa (arrow c). Note that
these inflammatory signs are
reduced by a 1-week
administration of Etoricoxib
(NGI ? ETORI1w) (circle e and
arrow f). cc cricoid cartilage,
pca posterior cricoarytenoid
muscle, L Laryngeal lumen.
a, d Hematoxylin–eosin
staining; b, c, e, f
immunohistochemistry for
COX-2 using DAB as
chromogen
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receptor (EP4 receptor-like immunoreactivity) at thin nerve
terminals and Prostaglandin E2 (PGE2) enhances CGRP
release [38]. It is also known that activation of mechano-
sensory nerves by COX-2 results from increasing levels of
Prostaglandin E2 (PGE2) [29]. Thus, in the larynx, COX-2
inhibitors may predominantly block PGE2 production and
CGRP depletion. At the end of the second week of NGI
Etoricoxib becomes ineffective in preventing CGRP (and
SP) depletion, which is in accordance with the loss of
efficacy already seen for the anti-inflammatory effects
observed for cytokine and COX-2 expression.
After this experimental therapeutic trial, we conclude
that NGI induces neurogenic laryngeal inflammation
through the release of neuropeptides SP and CGRP by
laryngeal sensitive fibres and, simultaneously, the overex-
pression of other inflammatory markers. The attenuation of
laryngitis induced by the selective COX-2 inhibitor
Etoricoxib at the first week of treatment indicates that this
drug can be administered during a limited period of time.
Moreover, our data suggest that Etoricoxib should be
evaluated in the future as an alternative drug option to
current treatment of laryngitis due to reduced side effects
comparatively to non-selective NSAIDs and corticosteroids
currently used in clinical practice. In support of this
hypothesis, recent clinical studies involving another
selective COX-2 inhibitor, Valdecoxib, demonstrated effi-
cacy with no significant side effects in a throat pain clinical
model of tonsillo-pharyngitis [17]. However, it should be
noted that prolonged treatment with Etoricoxib may be
unfavourable due to its pro-inflammatory reaction profile,
as shown in the present NGI model.
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Fig. 8 Histological changes in
the connective tissue of the
laryngeal mucosa induced by
nasogastric intubation (NGI) for
2 weeks. The presence of a
significant inflammatory
infiltrate after NGI as compared
to CONT is evident (circles a,
d). Inflammatory signs are also
present in intubated animals
subjected to vehicle for 2 weeks
(NGI ? VEHIC2w), namely
inflammatory cells (circle b),
edema and hypertrophy of the
mucosa (c). After 2 weeks of
NGI, these inflammatory signs
are not reduced
by administration of Etoricoxib
(NGI ? ETORI2w) (circle e, f).
cc cricoid cartilage, lca lateral
cricoarytenoid muscle,
L Laryngeal lumen.
a, d Hematoxylin–eosin
staining; b, c, e, f
immunohistochemistry
for COX-2 using DAB as
chromogen
M. Lima-Rodrigues et al.
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